Trevi Therapeutics, Inc. financial data

Symbol
TRVI on Nasdaq
Location
New Haven, CT
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1740% % 55%
Debt-to-equity 7% % -41%
Return On Equity -31% % 51%
Return On Assets -29% % 49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 128,230,134 shares 67%
Common Stock, Shares, Outstanding 128,215,113 shares 70%
Entity Public Float $179,700,000 USD 70%
Common Stock, Value, Issued $128,000 USD 71%
Weighted Average Number of Shares Outstanding, Basic 145,104,986 shares 43%
Weighted Average Number of Shares Outstanding, Diluted 145,104,986 shares 43%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $36,613,000 USD 0.13%
General and Administrative Expense $14,737,000 USD 27%
Operating Income (Loss) $51,350,000 USD -6.5%
Nonoperating Income (Expense) $5,462,000 USD 41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $45,888,000 USD -3.5%
Income Tax Expense (Benefit) $30,000 USD -3.4%
Net Income (Loss) Attributable to Parent $45,858,000 USD -3.5%
Earnings Per Share, Basic 0 USD/shares 16%
Earnings Per Share, Diluted 0 USD/shares 16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $56,869,000 USD 254%
Marketable Securities, Current $138,058,000 USD 179%
Other Assets, Current $1,997,000 USD 199%
Assets, Current $198,299,000 USD 194%
Property, Plant and Equipment, Net $213,000 USD 22%
Operating Lease, Right-of-Use Asset $741,000 USD -24%
Other Assets, Noncurrent $103,000 USD -60%
Assets $199,356,000 USD 189%
Accounts Payable, Current $2,709,000 USD 68%
Accrued Liabilities, Current $6,036,000 USD -16%
Liabilities, Current $9,041,000 USD -0.9%
Operating Lease, Liability, Noncurrent $527,000 USD -35%
Liabilities $9,568,000 USD -3.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax $30,000 USD -78%
Retained Earnings (Accumulated Deficit) $321,488,000 USD -17%
Stockholders' Equity Attributable to Parent $189,788,000 USD 222%
Liabilities and Equity $199,356,000 USD 189%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,477,000 USD -29%
Net Cash Provided by (Used in) Financing Activities $8,705,000 USD
Net Cash Provided by (Used in) Investing Activities $9,951,000 USD -23%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 128,215,113 shares 70%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,723,000 USD 21%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56,869,000 USD 254%
Deferred Tax Assets, Valuation Allowance $82,449,000 USD 19%
Deferred Tax Assets, Gross $82,800,000 USD 18%
Operating Lease, Liability $823,000 USD -22%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $45,967,000 USD -4.6%
Lessee, Operating Lease, Liability, to be Paid $937,000 USD -26%
Property, Plant and Equipment, Gross $385,000 USD 10%
Operating Lease, Liability, Current $296,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year Two $380,000 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $371,000 USD 6.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $114,000 USD -47%
Lessee, Operating Lease, Liability, to be Paid, Year Three $95,000 USD -75%
Deferred Tax Assets, Operating Loss Carryforwards $53,797,000 USD 6.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $95,000 USD -75%
Operating Lease, Payments $347,000 USD 22%
Additional Paid in Capital $511,118,000 USD 53%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $37,000 USD 5.7%
Interest Expense $9,000 USD -99%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%